Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Vincent Milano acquired 647 shares of BioCryst Pharmaceuticals common stock at $8.69 per share in lieu of a portion of his quarterly board member retainer.

Summary

• On August 30, 2024, Vincent Milano, a director of BioCryst Pharmaceuticals, acquired 647 shares of common stock.
• The shares were issued in lieu of 50% of his quarterly cash Board Member retainer of $11,250.
• The price per share was $8.69.
• Following the transaction, Milano directly owns 75,334 shares of BioCryst Pharmaceuticals.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction related to director compensation. The director taking shares instead of cash is a mildly positive signal.

Positives

• Director's decision to take shares instead of cash may signal confidence in the company's future.

Industry Context

Directors receiving shares in lieu of cash compensation is a common practice, particularly in growth-oriented companies, as it aligns their interests with those of shareholders.

Comparison to Industry Standards

• Comparing the director's shareholding to those of directors at similar-sized pharmaceutical companies (e.g., Xencor, Arcus Biosciences) could provide context on the significance of his stake.
• The decision to accept shares in lieu of cash is not uncommon among board members in the biotech industry, especially in companies focused on growth and development, such as Madrigal Pharmaceuticals or Viking Therapeutics.

Related Party Transactions

• The issuance of shares to Vincent Milano in lieu of cash compensation is a related party transaction.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It could be viewed positively by shareholders as it aligns the director's interests with theirs.

Key Dates